Immunomodulation of endothelial differentiated mesenchymal stromal cells: Impact on T and NK cells

Immunology and Cell Biology

Volumn 94, Issue 4, 2016, Pages 342-356

  El Omar, Reine ^a   Xiong, Yu ^a,b   Dostert, Gabriel ^a   Louis, Huguette ^a   Gentils, Monique ^a   Menu, Patrick ^a   Stoltz, Jean François ^a,b   Velot, Émilie ^a   Decot, Véronique ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; CD31 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; 5' NUCLEOTIDASE; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; BLOOD SAMPLING; CD25+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; TISSUE ENGINEERING; UMBILICAL CORD; UPREGULATION; WESTERN BLOTTING; FEMALE; GENETICS; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PHYSIOLOGY; REGULATORY T LYMPHOCYTE;

5'-NUCLEOTIDASE; ANTIGENS, CD31; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 84948399159     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.94     Document Type: Article

References (84)

1. Kurobe H, Maxfield MW, Breuer CK, Shinoka T. Concise review: tissue-engineered vascular grafts for cardiac surgery: past, present, and future. Stem Cells Transl Med 2012; 1: 566-571.
2. Caplan A. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217: 318-324.
3. El Omar R, Beroud J, Stoltz JF, Menu P, Velot E, Decot V. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell based therapies? Tissue Eng Part B Rev 2014; 20: 523-544.
4. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12: 574-591.
5. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal CCS 2011; 9: 12.
6. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J et al. Generation and accumulation of immunosuppressive adenosine by human CD4 +CD25highFOXP3+ regulatory T cells. J Biol Chem 2010; 285: 7176-7186.
7. Cuerquis J, Romieu-Mourez R, François M, Routy J-P, Young YK, Zhao J et al. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation. Cytotherapy 2014; 16: 191-202.
8. La Rocca G, Corrao S, Lo Iacono M, Corsello T, Farina F, Anzalone R. Novel immunomodulatory markers expressed by human WJ-MSC: an updated review in regenerative and reparative medicine. Open Tissue Eng Regen Med J 2012; 5: 50-58.
9. Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D et al. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett 2012; 146: 50-56.
10. Pietilä M, Lehtonen S, Tuovinen E, Lähteenmäki K, Laitinen S, Leskelä H-V et al. CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells. PLoS ONE 2012; 7: e31671.
11. Whiteside TL, Mandapathil M, Schuler P. The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem 2011; 18: 5217-5223.
12. Yen BL, Chang CJ, Liu K-J, Chen YC, Hu H-I, Bai C-H et al. Brief report-human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cells Dayt Ohio 2009; 27: 451-456.
13. Song H, Park H, Kim J, Park G, Kim Y-S, Kim SM et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol Lett 2011; 136: 187-193.
14. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
15. Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ, Cao T. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol Baltim Md 1950 2006; 176: 2864-2871.
16. Liu C-T, Yang Y-J, Yin F, Wang X, Yu X-H, Wang Q-H et al. The immunobiological development of human bone marrow mesenchymal stem cells in the course of neuronal differentiation. Cell Immunol 2006; 244: 19-32.
17. Huang X-P, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010; 122: 2419-2429.
18. Li P, Li S-H, Wu J, Zang W-F, Dhingra S, Sun L et al. Interleukin-6 downregulation with mesenchymal stem cell differentiation results in loss of immunoprivilege. J Cell Mol Med 2013; 17: 1136-1145.
19. Liu S, Yuan M, Hou K, Zhang L, Zheng X, Zhao B et al. Immune characterization of mesenchymal stem cells in human umbilical cord Wharton's jelly and derived cartilage cells. Cell Immunol 2012; 278: 35-44.
20. Zhang P, Baxter J, Vinod K, Tulenko TN, Di Muzio PJ. Endothelial differentiation of amniotic fluid-derived stem cells: synergism of biochemical and shear force stimuli. Stem Cells Dev 2009; 18: 1299-1308.
21. Janeczek Portalska K, Leferink A, Groen N, Fernandes H, Moroni L, van Blitterswijk C et al. Endothelial differentiation of mesenchymal stromal cells. PLoS ONE 2012; 7: e46842.
22. Rammal H, Beroud J, Gentils M, Labrude P, Menu P, Kerdjoudj H et al. Reversing charges or how to improve Wharton's jelly mesenchymal stem cells culture on polyelectrolyte multilayer films. Biomed Mater Eng 2013; 23: 299-309.
23. Boura C, Menu P, Payan E, Picart C, Voegel JC, Muller S et al. Endothelial cells grown on thin polyelectrolyte mutlilayered films: an evaluation of a new versatile surface modification. Biomaterials 2003; 24: 3521-3530.
24. Kronsteiner B, Wolbank S, Peterbauer A, Hackl C, Redl H, van Griensven M et al. Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev 2011; 20: 2115-2126.
25. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes 2009; 58: 1797-1806.
26. Park M-J, Shin J-S, Kim Y-H, Hong S-H, Yang S-H, Shin J-Y et al. Murine mesenchymal stem cells suppress T lymphocyte activation through IL-2 receptor α (CD25) cleavage by producing matrix metalloproteinases. Stem Cell Rev 2011; 7: 381-393.
27. Benson HL, Mobashery S, Chang M, Kheradmand F, Hong JS, Smith GN et al. Endogenous matrix metalloproteinases 2 and 9 regulate activation of CD4+ and CD8+ T cells. Am J Respir Cell Mol Biol 2011; 44: 700-708.
28. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow sources. Cell Immunol 2010; 264: 171-179.
29. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol Baltim Md 1950 2006; 176: 6752-6761.
30. Yan Z, Zhuansun Y, Chen R, Li J, Ran P. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Exp Cell Res 2014; 324: 65-74.
31. Luz-Crawford P, Kurte M, Bravo-Alegria J, Contreras R, Nova-Lamperti E, Tejedor G et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 2013; 4: 65.
32. Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013; 31: 1980-1991.
33. Chatterjee D, Tufa DM, Baehre H, Hass R, Schmidt RE, Jacobs R. Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells. Blood 2014; 123: 594-595.
34. Lee B-K, Kim M-J, Jang H-S, Lee H-R, Ahn K-M, Lee J-H et al. A high concentration of MMP-2/gelatinase A and MMP-9/gelatinase B reduce NK cell-mediated cytotoxicity against an oral squamous cell carcinoma cell line. Vivo Athens Greece 2008; 22: 593-597.
35. Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21: 356-359. author reply 359.
36. Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J Immunol Baltim Md 1950 1991; 147: 3459-3465.
37. Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation 2003; 108: 3122-3127.
38. Nowak G, Karrar A, Holmén C, Nava S, Uzunel M, Hultenby K et al. Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization. Circulation 2004; 110: 3699-3707.
39. Chen M-Y, Lie P-C, Li Z-L, Wei X. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Exp Hematol 2009; 37: 629-640.
40. Vater C, Kasten P, Stiehler M. Culture media for the differentiation of mesenchymal stromal cells. Acta Biomater 2011; 7: 463-477.
41. Prasad Chennazhy K, Krishnan LK. Effect of passage number and matrix characteristics on differentiation of endothelial cells cultured for tissue engineering. Biomaterials 2005; 26: 5658-5667.
42. La Rocca G, Lo Iacono M, Corsello T, Corrao S, Farina F, Anzalone R. Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr Stem Cell Res Ther 2013; 8: 100-113.
43. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
44. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells Dayt Ohio 2004; 22: 377-384.
45. Niwa K, Kado T, Sakai J, Karino T. The effects of a shear flow on the uptake of LDL and acetylated LDL by an EC monoculture and an EC-SMC coculture. Ann Biomed Eng 2004; 32: 537-543.
46. Fischer LJ, McIlhenny S, Tulenko T, Golesorkhi N, Zhang P, Larson R et al. Endothelial differentiation of adipose-derived stem cells: effects of endothelial cell growth supplement and shear force. J Surg Res 2009; 152: 157-166.
47. Montespan F, Deschaseaux F, Sensébé L, Carosella ED, Rouas-Freiss N. Osteodifferentiated mesenchymal stem cells from bone marrow and adipose tissue express HLA-G and display immunomodulatory properties in HLA-mismatched settings: implications in bone repair therapy. J Immunol Res 2014; 2014: e230346.
48. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol Baltim Md 1950 2004; 172: 7393-7398.
49. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells Dayt Ohio 2006; 24: 74-85.
50. Castro-Manrreza ME, Mayani H, Monroy-García A, Flores-Figueroa E, Chávez-Rueda K, Legorreta-Haquet V et al. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev 2014; 23: 1217-1232.
51. Chinnadurai R, Copland IB, Patel SR, Galipeau J. IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J Immunol 2014; 192: 1491-1501.
52. Le Blanc K, Rasmusson I, Götherström C, Seidel C, Sundberg B, Sundin M et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004; 60: 307-315.
53. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36: 309-318.
54. Luan X, Li G, Wang G, Wang F, Lin Y. Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34+ cells: a comparison with human bone marrow-derived mesenchymal stem cells. Tissue Cell 2013; 45: 32-38.
55. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 2010; 88: 795-806.
56. Manochantr S, U-pratya Y, Kheolamai P, Rojphisan S, Chayosumrit M, Tantrawatpan C et al. Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord. Intern Med J 2013; 43: 430-439.
57. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-629.
58. Nissinen L, Kähäri V-M. Matrix metalloproteinases in inflammation. Biochim Biophys Acta 2014; 1840: 2571-2580.
59. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells Dayt Ohio 2008; 26: 212-222.
60. Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 2005; 90: 516-525.
61. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
62. Lu L, Feng M, Gu J, Xia Z, Zhang H, Zheng S et al. Restoration of intrahepatic regulatory T cells through MMP-9/13-dependent activation of TGF-β is critical for immune homeostasis following acute liver injury. J Mol Cell Biol 2013; 5: 369-379.
63. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
64. Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC. Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 2005; 332: 370-379.
65. Ganesh BB, Bhattacharya P, Gopisetty A, Sheng J, Vasu C, Prabhakar BS. IL-1β promotes TGF-β1 and IL-2 dependent Foxp3 expression in regulatory T cells. PLoS ONE 2011; 6: e21949.
66. Afzali B, Mitchell PJ, Edozie FC, Povoleri GAM, Dowson SE, Demandt L et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur J Immunol 2013; 43: 2043-2054.
67. Curran T-A, Jalili RB, Farrokhi A, Ghahary A. IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells. Immunobiology 2014; 219: 17-24.
68. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009; 114: 555-563.
69. Park M-J, Min S-Y, Park K-S, Cho Y-G, Cho M-L, Jung Y-O et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collageninduced arthritis mouse model. Arthritis Res Ther 2008; 10: R11.
70. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25-into CD25+ T regulatory cells. Blood 2007; 109: 2871-2877.
71. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol Baltim Md 1950 2012; 188: 21-28.
72. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333.
73. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 2014; 5: 1038-1051.
74. Chauveau A, Tonnerre P, Pabois A, Gavlovsky P-J, Chatelais M, Coupel S et al. Endothelial cell activation and proliferation modulate NKG2D activity by regulating MICA expression and shedding. J Innate Immun 2014; 6: 89-104.
75. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008; 32: 527-535.
76. Häusler SFM, Montalbán del Barrio I, Strohschein J, Anoop Chandran P, Engel JB, Hönig A et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother CII 2011; 60: 1405-1418.
77. Petsa A, Gargani S, Felesakis A, Grigoriadis N, Grigoriadis I. Effectiveness of protocol for the isolation of Wharton's Jelly stem cells in large-scale applications. Vitro Cell Dev Biol Anim 2009; 45: 573-576.
78. Harmouch C, El-Omar R, Labrude P, Decot V, Menu P, Kerdjoudj H. Influence of serum percentage on the behavior of Wharton's jelly mesenchymal stem cells in culture. Biomed Mater Eng 2013; 23: 273-280.
79. Xu Y, Meng H, Li C, Hao M, Wang Y, Yu Z et al. Umbilical cord-derived mesenchymal stem cells isolated by a novel explantation technique can differentiate into functional endothelial cells and promote revascularization. Stem Cells Dev 2010; 19: 1511-1522.
80. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
81. Doan CC, Le TL, Hoang NS, Doan NT, Le VD, Si, Do M. Differentiation of umbilical cord lining membrane-derived mesenchymal stem cells into endothelial-like cells. Iran Biomed J 2014; 18: 67-75.
82. Decot V, Voillard L, Latger-Cannard V, Aissi-Rothé L, Perrier P, Stoltz JF et al. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol 2010; 38: 351-362.
83. Poleni P-E, Etienne S, Velot E, Netter P, Bianchi A. Activation of PPARs α, β/δ, and γ impairs TGF-β1-induced collagens' production and modulates the TIMP-1/MMPs balance in three-dimensional cultured chondrocytes. PPAR Res 2010; 2010: 635912.
84. Ernens I, Rouy D, Velot E, Devaux Y, Wagner DR. Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils: implication of A2a receptor and cAMP/ PKA/Ca2+ pathway. Circ Res 2006; 99: 590-597.